Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective

Authors Macaulay R, Ahuja A, Ademisoye E, Juarez-Garcia A, Shaw JW

Received 23 June 2018

Accepted for publication 29 October 2018

Published 19 March 2019 Volume 2019:11 Pages 199—219

DOI https://doi.org/10.2147/CEOR.S177343

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 3

Editor who approved publication: Professor Samer Hamidi


Video abstract presented Richard Macaulay.

Views: 66

Richard Macaulay,1 Amit Ahuja,2 Ebenezer Ademisoye,1 Ariadna Juarez-Garcia,3 James W Shaw4

1PAREXEL Access Consulting, London, UK; 2PAREXEL Access Consulting, Union Territory of Chandigarh, India; 3Bristol-Myers Squibb, Mexico City, Mexico; 4Bristol-Myers Squibb, Princeton, NJ, USA

Objectives: The introduction of innovative, high-cost oncology treatments, coupled with mounting budgetary pressures, necessitates value trade-offs across cancer types. Defining value is critical to informing decision-making. A cost-value analysis tool was used to assess relative clinical value from a US perspective using multiple outcome metrics for a variety of metastatic cancers.
Methods: Literature published (January 1, 2000–August 31, 2016) was reviewed to identify outcome metrics for approved treatments for metastatic cancers. Data were extracted or derived for median and mean overall survival (OS), landmark survival rates, and other survival metrics, and compared across treatments vs their respective trial comparators, with and without considering costs.
Results: Reported survival metrics varied by agent within cancer type. For treatment of prostate cancer, abiraterone yielded the highest improvement in 1-year survival rate (13.7%, previously treated), whereas enzalutamide yielded the highest median OS improvement (4.8 months, previously treated) and sipuleucel-T, the highest mean OS improvement (3.6 months, previously untreated) vs their respective trial comparators. For treatment of non-small cell lung cancer vs their respective trial comparators, nivolumab yielded the highest improvement in mean OS (11.9 months) and 3-year survival rate (12.6%), each in previously treated squamous disease, whereas afatinib yielded the highest median OS improvement (4.1 months, previously untreated EGFR del19 and L858R mutants). Cost-value analysis results varied with the applied survival metric.
Conclusions: Although median OS is the traditional gold standard oncology efficacy metric, it fails to capture long-term survival benefits—the ultimate goal of cancer treatment—offered by new treatment modalities. Diverse metrics are needed for comprehensive value assessments of cancer therapies.

Keywords: value framework, value assessment, immuno-oncology, cost-value analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]